I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 M{PTfYN6fG:2b4jpZ4l1gSCjc4PhfS=> MkfBglExOCEQvF2= MXvEUXNQ MnrjTWM2OD1{NjDuUS=> NIfZfpEzOTl4NEO0NC=>
RS4;11 NIPpdG1kgXSxdH;4bYNqfHliYYPzZZk> MX;+NVAxKM7:TR?= NIHjfW9FVVOR M{jqPGlEPTB;MUmyJI5O M{exfFIyQTZ2M{Sw
MOLM13 MknCZ5l1d3SxeHnjbZR6KGG|c3H5 MWX+NVAxKM7:TR?= MoD6SG1UVw>? MUHJR|UxRTF{MDDuUS=> NVvTZod[OjF7NkSzOFA>
NOMO1 NFe1[2FkgXSxdH;4bYNqfHliYYPzZZk> MWn+NVAxKM7:TR?= MXLEUXNQ MnPJTWM2OD1zNTDuUS=> NELOXmMzOTl4NEO0NC=>
HEL MUPjfZRwfG:6aXPpeJkh[XO|YYm= MUL+NVAxKM7:TR?= NXjuT2lFTE2VTx?= NVHHdW9XUUN3ME2xJO69VQ>? M2fETVIyQTZ2M{Sw
K562 NHTMWoJkgXSxdH;4bYNqfHliYYPzZZk> NYXoZXE5hjFyMDFOwG0> NW\tT25DTE2VTx?= NET1[XhKSzVyPkGwNEDPxE1? Mne1NlE6PjR|NEC=
MEG01 MofJZ5l1d3SxeHnjbZR6KGG|c3H5 MYj+NVAxKM7:TR?= MVvEUXNQ NUf3[HVEUUN3ME2yOUDPxE1? M3jWfVIyQTZ2M{Sw
HL60 MofXZ5l1d3SxeHnjbZR6KGG|c3H5 NUHyWHNLhjFyMDFOwG0> MVTEUXNQ NXu5[Y1CUUN3ME24PVAhdk1? NULBb21POjF7NkSzOFA>
MV4;11 NIPFZ4RCeG:ydH;zbZMh[XO|YYm= M{\WWp4yODBizszN MnvFSG1UVw>? MW\pcoR2[2W|IHHwc5B1d3Orcx?= MXqyNVk3PDN2MB?=
MOLM13 NXmyfWtSSXCxcITvd4l{KGG|c3H5 MmLYglExOCEQvF2= MmD4SG1UVw>? MX\pcoR2[2W|IHHwc5B1d3Orcx?= M2\DRVIyQTZ2M{Sw
MV4;11 MmTBSpVv[3Srb36gZZN{[Xl? M4DVWmROW09? NHjkdFJl\WO{ZXHz[ZMhfGinIILlZ5J2cXSvZX70JI9nKEKUREOvOEBidmRiaX3wZYlz\WRicnXjdpVqfG2nboSgc4YhS0SNOTDhcoQhWEGIMTD0c{B1cGVidILhcpNkemmydHnvcoFtKHO2YYL0JJNqfGV? NUH1OGRLOjF7NkSzOFA>
PBMC NWLx[FQ5TnWwY4Tpc44h[XO|YYm= Ml7MSG1UVw>? NIruUG5qdmirYnn0d{BKVC14IIfpeIgheEmFNUCgc4YhPi55 NV\rfnh6OjJ2M{exNVU>
A2 MYfGeY5kfGmxbjDhd5NigQ>? MkPJglExKM7:TR?= MnPGSG1UVw>? MmXrdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z M2niZ|I{OjV3MkG4
A72 NWmybFRKTnWwY4Tpc44h[XO|YYm= M4LNZ54yOCEQvF2= MmriSG1UVw>? M4GxcpJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= NHG1TpEzOzJ3NUKxPC=>
BC1 Mo\lS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1rMR54yKM7:TR?= M1THRWROW09? M2jLeWlEPTB;MkKwJI5O M1rhTVI{Pzl{NES4
BC3 MoflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVHxVIhbhjFizszN M1rnTGROW09? NUSzdFBDUUN3ME20OlAhdk1? M3\UTVI{Pzl{NES4
BCBL1 M2LlPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUj+NUDPxE1? MljmSG1UVw>? NXTMZ25WUUN3ME2zN|Ahdk1? NWPsTJRnOjN5OUK0OFg>
BJAB M332Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHfMXHd,OSEQvF2= NFvnXZpFVVOR MV7JR|UxRTl5MDDuUS=> MVOyN|c6OjR2OB?=
Namalwa NYTITY9TT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXj+NUDPxE1? NVHzWm5FTE2VTx?= NFf4fXRKSzVyPUm3NEBvVQ>? Mme0NlM4QTJ2NEi=
Jurkat NXrJcJI1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoXCglEh|ryP M{TiW2ROW09? MV3JR|UxRTF{MkCgcm0> MlnaNlM4QTJ2NEi=
MM1S NGqxOWtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2rvUp4yKM7:TR?= M{nkXWROW09? M3jwS2lEPTB;N{[wJI5O NFP2WGQzOzd7MkS0PC=>
U266 MofjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4PiPZ4yKM7:TR?= NGW3VlNFVVOR NH;WT5hKSzVyPUm1NEBvVQ>? NWPONY9[OjN5OUK0OFg>
UM-PEL-1 NEnENVRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHXqN4d,OSEQvF2= M3jqVmROW09? MUPJR|UxRTJzMDDuUS=> M{XEZlI{Pzl{NES4
UM-PEL-3 NHHtN2tIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWT+NUDPxE1? NVzHXZVbTE2VTx?= NX7HPHNNUUN3ME2xPFAhdk1? M2fqSVI{Pzl{NES4
BC1 NEW1ZpJHfW6ldHnvckBie3OjeR?= MlPyOVAxKG6P Mm\wSG1UVw>? M{f6fYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NGjCbo0zOzd7MkS0PC=>
BC3 NGD3Um1HfW6ldHnvckBie3OjeR?= MnX6OVAxKG6P M4XxUWROW09? NFTMbJpqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MUmyN|c6OjR2OB?=
BC1 NV3UcYZyTnWwY4Tpc44h[XO|YYm= MoroPFAxKG6P NUfuU|h6TE2VTx?= MX;y[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz MUSyN|c6OjR2OB?=
BC3 NWe1VHB{TnWwY4Tpc44h[XO|YYm= NWD5VWQ2QDByIH7N Mni5SG1UVw>? NEKx[WZz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ Mmq4NlM4QTJ2NEi=
H929 NF;IZ4hHfW6ldHnvckBie3OjeR?= NHHl[2J,OSEQvF2= MnvGSG1UVw>? NHT1V3dqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NHviR4szPDN|NUS5PS=>
KMS12PE MVrGeY5kfGmxbjDhd5NigQ>? NYP1S2J3hjFizszN MUTEUXNQ MV\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MnTtNlQ{OzV2OUm=
KMS12BM MYPGeY5kfGmxbjDhd5NigQ>? NHHDOZd,OSEQvF2= M1TIe2ROW09? Ml7JbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MmT3NlQ{OzV2OUm=
KMS18 NIO1bHFHfW6ldHnvckBie3OjeR?= MV;+NUDPxE1? MV;EUXNQ MoLYbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MYmyOFM{PTR7OR?=
KMS11 MkjnSpVv[3Srb36gZZN{[Xl? MmLFglEh|ryP MUDEUXNQ MoXXbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MXWyOFM{PTR7OR?=
RPMI8226 M{HZN2Z2dmO2aX;uJIF{e2G7 MXT+NUDPxE1? MUHEUXNQ MWfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MVGyOFM{PTR7OR?=
H929 NX;wTVY5SXCxcITvd4l{KGG|c3H5 MWL+NUDPxE1? MlnoSG1UVw>? MlLKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NW\zXG92OjR|M{W0PVk>
KMS12PE MUTBdI9xfG:|aYOgZZN{[Xl? NVTacGl1hjFizszN M3rtUWROW09? MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVKyOFM{PTR7OR?=
KMS12BM M1;n[WFxd3C2b4Ppd{Bie3OjeR?= MmrwglEh|ryP M2DYUmROW09? M2nBfolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mof6NlQ{OzV2OUm=
KMS18 MXjBdI9xfG:|aYOgZZN{[Xl? MW\+NUDPxE1? NIr4[npFVVOR M1PlUolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MYGyOFM{PTR7OR?=
KMS11 MV3BdI9xfG:|aYOgZZN{[Xl? NV2wTYxwhjFizszN NEmyfoRFVVOR M2nUXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmDCNlQ{OzV2OUm=
RPMI8226 NHLzb3NCeG:ydH;zbZMh[XO|YYm= MWr+NUDPxE1? NUewWGxHTE2VTx?= MnXKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mk\lNlQ{OzV2OUm=
U87MG MXfGeY5kfGmxbjDhd5NigQ>? NUPLcWhvhjFyIN88US=> MWjEUXNQ MYPy[YR2[2W|IGW4O21IKGOnbHz1cIFzKEGWUDD3bZRpKEmFNUCgc4YhOS5yNTFOwG0> NILmUZIzPDR7NkO4NS=>
A172 MWjGeY5kfGmxbjDhd5NigQ>? NF:wXlJ,OTBizszN NEDRfY1FVVOR MUny[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6yPEDPxE1? MV2yOFQ6PjN6MR?=
SW1783 NVHwO4NNTnWwY4Tpc44h[XO|YYm= M16yeJ4yOCEQvF2= NFfYXGRFVVOR NX\EU5BLemWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFIvPjhizszN M1jjVFI1PDl4M{ix
U87MG NGrFbnlHfW6ldHnvckBie3OjeR?= NEe2[ml,OTBizszN M3HyTGROW09? NWXYUFNHcW6lcnXhd4V{KHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6geIhmKEdzL2OgeJJidnOrdHnvci=> M4jEcVI1PDl4M{ix
RAW267.4 M3jTT2Z2dmO2aX;uJIF{e2G7 MUmxJO69VQ>? MYjEUXNQ NYLmUFByemWmdXPld{BKVC14IIDyc4R2[3Srb36gbY5lfWOnZDDifUBNWFN? MknwNlQ5PTlyMEi=
RAW267.4 MlPuSpVv[3Srb36gZZN{[Xl? MVWxJO69VQ>? M{X3PWROW09? MoXudoVlfWOnczD0bIUh[XO|b3PpZZRqd25iYnX0e4VmdiCEUlS0JIFv\CCjY3X0fYxifGWmIIC2OS=> M37Db|I1QDV7MEC4
Me007 NUG3Z3c1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{DqWp4yODBizszN M{X0SmROW09? MW\pcohq[mm2czD0bIUh\3Kxd4To MVGyOFkxPjF|Nx?=
SK-Mel-28 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHf0W4x,OTByIN88US=> NWHSNm1kTE2VTx?= MnvDbY5pcWKrdIOgeIhmKGe{b4f0bC=> M4jPfFI1QTB4MUO3
Mel-RMU NUjpfJdoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkXMglExOCEQvF2= NH;3PG1FVVOR NEL2d5NqdmirYnn0d{B1cGViZ4Lve5Rp NWLGU2dKOjR7ME[xN|c>
Mel-JD NW\SfnVsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MU\+NVAxKM7:TR?= M{jPdGROW09? NYj6[Wl[cW6qaXLpeJMhfGinIHfyc5d1cA>? M2rrd|I1QTB4MUO3
Mel-RM MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH;0eYV,OTByIN88US=> MlHBSG1UVw>? MX7pcohq[mm2czD0bIUh\3Kxd4To MojiNlQ6ODZzM{e=
Me007 NXHLPYVqSXCxcITvd4l{KGG|c3H5 NYXkVmtJhjFyMDFOwG0> NYTGTHVsTE2VTx?= MXrpcoR2[2W|IHHwc5B1d3Orcx?= NF[4PHczPDlyNkGzOy=>
SK-Mel-28 MoXVRZBweHSxc3nzJIF{e2G7 NHTYc2x,OTByIN88US=> NWWwdHpbTE2VTx?= MlXpbY5lfWOnczDhdI9xfG:|aYO= NWfGdppbOjR7ME[xN|c>
Mel-RMU NYS1[YhJSXCxcITvd4l{KGG|c3H5 NXHlWGNxhjFyMDFOwG0> MXnEUXNQ MWTpcoR2[2W|IHHwc5B1d3Orcx?= MXSyOFkxPjF|Nx?=
Mel-JD MWPBdI9xfG:|aYOgZZN{[Xl? M3v3Np4yODBizszN NH[zeIZFVVOR NFPPPItqdmS3Y3XzJIFxd3C2b4Ppdy=> NHzr[oIzPDlyNkGzOy=>
Mel-RM NF\FWY9CeG:ydH;zbZMh[XO|YYm= MmDqglExOCEQvF2= NFjkS3VFVVOR M4rtbIlv\HWlZYOgZZBweHSxc3nz MVKyOFkxPjF|Nx?=
Me007 MkLZSpVv[3Srb36gZZN{[Xl? MXmxNEDPxE1? MlTRSG1UVw>? MnzTbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NIH0SoYzPDlyNkGzOy=>
SK-Mel-28 NWHFb4dyTnWwY4Tpc44h[XO|YYm= M1u1SVExKM7:TR?= NY\ac2t7TE2VTx?= NYXPdm1bcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz MonNNlQ6ODZzM{e=
Mel-RMU M{fCZmZ2dmO2aX;uJIF{e2G7 NW[2TIN6OTBizszN NID5XmdFVVOR NH3PS5hqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NUOxXHE6OjR7ME[xN|c>
Mel-JD M4PlWGZ2dmO2aX;uJIF{e2G7 MWCxNEDPxE1? MXvEUXNQ M4nHdolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? Mn7mNlQ6ODZzM{e=
Mel-RM NXvYPHc{TnWwY4Tpc44h[XO|YYm= NGfp[WQyOCEQvF2= MXnEUXNQ MmnrbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy Moj3NlQ6ODZzM{e=
Me007 M1\NNGZ2dmO2aX;uJIF{e2G7 NFe0UmoyOCEQvF2= MoHISG1UVw>? NWDJe3dJfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MVSyOFkxPjF|Nx?=
SK-Mel-28 MnH3SpVv[3Srb36gZZN{[Xl? MUWxNEDPxE1? MlfDSG1UVw>? NX3Ie5FHfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NX\qZotnOjR7ME[xN|c>
Mel-RMU M2rhNmZ2dmO2aX;uJIF{e2G7 NIPobYgyOCEQvF2= NV;CUZROTE2VTx?= NIqzS3F2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NF\OOWIzPDlyNkGzOy=>
Mel-JD M1;HPWZ2dmO2aX;uJIF{e2G7 M{f3UFExKM7:TR?= MXjEUXNQ MVn1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| M4OxUFI1QTB4MUO3
Mel-RM M{\xS2Z2dmO2aX;uJIF{e2G7 NF:0XmoyOCEQvF2= NFix[HhFVVOR MYX1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| Mn3RNlQ6ODZzM{e=

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO <1 mg/mL
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID